BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26854974)

  • 1. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
    Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
    Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
    Steiner G
    Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
    Keating GM
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
    Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
    Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
    Koh KK; Quon MJ; Shin KC; Lim S; Lee Y; Sakuma I; Lee K; Han SH; Shin EK
    Atherosclerosis; 2012 Feb; 220(2):537-44. PubMed ID: 22153696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
    Tan CE; Chew LS; Tai ES; Chio LF; Lim HS; Loh LM; Shepherd J
    Atherosclerosis; 2001 Feb; 154(2):469-74. PubMed ID: 11166781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
    Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
    Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
    Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
    Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Extended-Release Niacin on Quartile Lp-PLA
    Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan.
    Hsu H; Hsu P; Cheng MH; Ito Y; Kanda E; Schaefer EJ; Ai M
    J Atheroscler Thromb; 2019 Oct; 26(10):890-914. PubMed ID: 30726792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
    Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
    Anderlová K; Dolezalová R; Housová J; Bosanská L; Haluzíková D; Kremen J; Skrha J; Haluzík M
    Physiol Res; 2007; 56(5):579-586. PubMed ID: 17184146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.